We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Xceleron and Organon Sign Microdose Study Agreement

Xceleron and Organon Sign Microdose Study Agreement

Xceleron and Organon Sign Microdose Study Agreement

Xceleron and Organon Sign Microdose Study Agreement

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Xceleron and Organon Sign Microdose Study Agreement"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Xceleron Ltd announced collaboration with Organon, the human healthcare business unit of Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development.

Xceleron says that it has been selected by Organon on the basis of fast and cost-effective delivery of human information that will enable them to make better choices in early drug development.

The three selected drug candidates are all compounds that have emerged from Organon’s gynaecological research and development activities. The purpose of the human microdose study is to assess all important pharmacokinetic properties of the compounds whilst confirming the scalability of the microdose to pharmacological dose for these compounds.

Xceleron will use its ultra-sensitive Accelerator Mass Spectrometry analytical technology to determine human plasma concentrations after microgram administration of the various drug candidates.

“Increasingly, leading pharmaceutical companies are adopting Xceleron’s new drug development strategies to maximise data on compounds in the exploratory clinical development phase” observed Xceleron’s founder and CEO Professor Colin Garner.

“We are delighted that Organon has further demonstrated its willingness to adopt innovative approaches to drug development and are proud to add them to Xceleron’s rapidly growing, international portfolio of human microdose supporters”, he added.

David Nicholson, Executive Vice-President Research & Development of Organon commented: “given previous positive experiences with Xceleron and its enabling technology we have commissioned this microdose study to examine important pharmacokinetic parameters in humans in order to aid confirmation of the best candidate for further development”.

Commenting on the value of the innovative human microdose approach he added: “the most compelling reason for using human microdosing is the speed with which we can gain results from human studies to make pivotal decisions”.